Arch Therapeutics Valuation
Is ARTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ARTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ARTH's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ARTH's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARTH?
Key metric: As ARTH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ARTH's PS Ratio? | |
|---|---|
| PS Ratio | 6x |
| Sales | US$148.16k |
| Market Cap | US$888.87k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 69.2x |
| Enterprise Value/EBITDA | -2.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ARTH's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.8x | ||
PCYN Procyon | 0.3x | n/a | US$1.6m |
IVRO InVitro International | 2.3x | n/a | US$1.8m |
VYCO Vycor Medical | 1.7x | n/a | US$2.9m |
VTAK Catheter Precision | 3x | 116.5% | US$1.2m |
ARTH Arch Therapeutics | 6x | n/a | US$888.9k |
Price-To-Sales vs Peers: ARTH is expensive based on its Price-To-Sales Ratio (6x) compared to the peer average (1.8x).
Price to Sales Ratio vs Industry
How does ARTH's PS Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: ARTH is expensive based on its Price-To-Sales Ratio (6x) compared to the US Medical Equipment industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is ARTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ARTH's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$93.6b
Operates as a health benefits company in the United States.
ELV
US$402.55
7D
0.5%
1Y
-15.9%
Lantheus Holdings
US$6.1b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$90.52
7D
17.8%
1Y
31.5%
electroCore
US$64.0m
A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
ECOR
US$11.21
7D
2.5%
1Y
101.6%